Low Rate of Thrombosis in Mexican Patients with COVID-19 Infection. a Benefit of Higher Doses Anticoagulants or a Sub Diagnosis?

Background: Patients with COVID-19 have an increased risk of thromboembolic disease, this has been partly attributed to an excessive inflammatory response that is associated with hypercoagulability; patients develop thrombotic complications with rates of 6.4% in non-critically ill and 15 to 31 % in...

Descripción completa

Detalles Bibliográficos
Autores principales: Marquez, Félix Gibrant, Riviello-Goya, Santiago, Vargas Ruiz, Angel Gabriel, Ortíz Brizuela, Edgar, Gil López, Fernando, Gutierrez Marín, Alfredo, Gonzalez Lara, María Fernanda, Ponce de Léon Garduño, Alfredo, Sifuentes Osornio, José, Rangel-Patiño, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
331.Pathophysiology of Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330371/
http://dx.doi.org/10.1182/blood-2020-136240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330371/
http://dx.doi.org/10.1182/blood-2020-136240

Ejemplares similares